ZIO-201 isophosphoramide mustard: Interim Phase I/II data

Interim data from 44 evaluable patients in the Phase II portion of an ongoing, open-label, U.S. Phase I/II trial showed that 48% of ZIO-201 patients had stable disease or better. Median progression-fr...